Skip to main content
LON:KMK

Kromek Group Competitors

GBX 15.10
-0.30 (-1.95 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
14.91
15.68
50-Day Range
15
16.28
52-Week Range
7
25.20
Volume1.74 million shs
Average Volume2.86 million shs
Market Capitalization£65.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Kromek Group (LON:KMK) Vs. EAH, ARIX, AGL, ORPH, BVXP, and POLX

Should you be buying KMK stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Kromek Group, including ECO Animal Health Group (EAH), Arix Bioscience (ARIX), ANGLE (AGL), Open Orphan (ORPH), Bioventix (BVXP), and Polarean Imaging (POLX).

Kromek Group (LON:KMK) and ECO Animal Health Group (LON:EAH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kromek Group and ECO Animal Health Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kromek Group0000N/A
ECO Animal Health Group00103.00

Profitability

This table compares Kromek Group and ECO Animal Health Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kromek GroupN/AN/AN/A
ECO Animal Health GroupN/AN/AN/A

Valuation and Earnings

This table compares Kromek Group and ECO Animal Health Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kromek Group£12.36 million5.27N/AGBX (5)-3.02
ECO Animal Health Group£86.32 million2.86N/AGBX 573.00

Kromek Group is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

Summary

ECO Animal Health Group beats Kromek Group on 4 of the 5 factors compared between the two stocks.

Kromek Group (LON:KMK) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kromek Group and Arix Bioscience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kromek Group0000N/A
Arix Bioscience01002.00

Profitability

This table compares Kromek Group and Arix Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kromek GroupN/AN/AN/A
Arix BioscienceN/AN/AN/A

Valuation and Earnings

This table compares Kromek Group and Arix Bioscience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kromek Group£12.36 million5.27N/AGBX (5)-3.02
Arix Bioscience£135.77 million1.81N/AGBX 88.702.08

Kromek Group is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Arix Bioscience beats Kromek Group on 3 of the 4 factors compared between the two stocks.

Kromek Group (LON:KMK) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kromek Group and ANGLE, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kromek Group0000N/A
ANGLE0000N/A

Profitability

This table compares Kromek Group and ANGLE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kromek GroupN/AN/AN/A
ANGLEN/AN/AN/A

Valuation and Earnings

This table compares Kromek Group and ANGLE's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kromek Group£12.36 million5.27N/AGBX (5)-3.02
ANGLE£762,000.00320.91N/AGBX (6.50)-17.46

ANGLE is trading at a lower price-to-earnings ratio than Kromek Group, indicating that it is currently the more affordable of the two stocks.

Summary

Kromek Group beats ANGLE on 3 of the 4 factors compared between the two stocks.

Kromek Group (LON:KMK) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Kromek Group and Open Orphan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kromek GroupN/AN/AN/A
Open OrphanN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kromek Group and Open Orphan, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kromek Group0000N/A
Open Orphan0000N/A

Given Open Orphan's higher possible upside, analysts clearly believe Open Orphan is more favorable than Kromek Group.

Valuation and Earnings

This table compares Kromek Group and Open Orphan's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kromek Group£12.36 million5.27N/AGBX (5)-3.02
Open Orphan£10.57 million22.13N/AGBX (3.20)-10.92

Open Orphan is trading at a lower price-to-earnings ratio than Kromek Group, indicating that it is currently the more affordable of the two stocks.

Summary

Open Orphan beats Kromek Group on 3 of the 5 factors compared between the two stocks.

Kromek Group (LON:KMK) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Kromek Group and Bioventix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kromek GroupN/AN/AN/A
BioventixN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Kromek Group and Bioventix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kromek Group0000N/A
Bioventix0000N/A

Earnings & Valuation

This table compares Kromek Group and Bioventix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kromek Group£12.36 million5.27N/AGBX (5)-3.02
Bioventix£10.38 million20.88N/AGBX 131.2031.71

Kromek Group is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Summary

Bioventix beats Kromek Group on 3 of the 4 factors compared between the two stocks.

Kromek Group (LON:KMK) and Polarean Imaging (LON:POLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Kromek Group and Polarean Imaging's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kromek GroupN/AN/AN/A
Polarean ImagingN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Kromek Group and Polarean Imaging, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kromek Group0000N/A
Polarean Imaging00103.00

Earnings & Valuation

This table compares Kromek Group and Polarean Imaging's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kromek Group£12.36 million5.27N/AGBX (5)-3.02
Polarean Imaging£2.23 million90.01N/AGBX (3.40)-28.24

Polarean Imaging is trading at a lower price-to-earnings ratio than Kromek Group, indicating that it is currently the more affordable of the two stocks.

Summary

Polarean Imaging beats Kromek Group on 3 of the 5 factors compared between the two stocks.


Kromek Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ECO Animal Health Group logo
EAH
ECO Animal Health Group
0.9$365.00-0.0%£247.12 million£86.32 million73.00
ARIX
Arix Bioscience
0.8$184.50-0.3%£246.03 million£135.77 million2.08
ANGLE logo
AGL
ANGLE
0.4$113.50-2.6%£244.54 million£762,000.00-17.46
ORPH
Open Orphan
0.0$34.95-5.3%£233.96 million£10.57 million-10.92
Bioventix logo
BVXP
Bioventix
0.8$4,160.00-0.2%£216.69 million£10.38 million31.71
POLX
Polarean Imaging
0.5$96.00-1.0%£200.67 million£2.23 million-28.24
Synairgen logo
SNG
Synairgen
1.1$100.10-0.8%£200.11 million£79,000.00-19.63Analyst Report
News Coverage
Gap Up
MGP
Medica Group
0.9$160.00-0.3%£195.83 million£41.55 million36.36Dividend Increase
Analyst Report
Redx Pharma logo
REDX
Redx Pharma
0.6$65.00-0.0%£178.03 million£5.69 million-12.04Gap Down
DDDD
4D pharma
0.6$96.00-1.0%£173.09 million£690,000.00-5.03Gap Down
ANCR
Animalcare Group
0.7$282.00-1.6%£169.36 million£70.49 million705.00
Scancell logo
SCLP
Scancell
0.6$20.75-1.2%£169.16 millionN/A-14.82
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$332.50-0.0%£167.77 million£2.12 million-10.33
ONC
Oncimmune
0.4$218.00-0.2%£150.63 million£2.03 million-23.96
Allergy Therapeutics logo
AGY
Allergy Therapeutics
0.8$23.25-1.1%£148.98 million£81.76 million23.25
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$72.00-3.5%£140.12 millionN/A-13.09News Coverage
Circassia Group logo
CIR
Circassia Group
0.9$33.50-2.2%£140.10 million£23.90 million-3.81
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50-1.9%£138.87 millionN/A-0.21Gap Down
Omega Diagnostics Group logo
ODX
Omega Diagnostics Group
0.3$72.00-0.0%£131.47 million£8.52 million-16.36
Futura Medical logo
FUM
Futura Medical
1.5$50.40-9.1%£129.03 million£31,778.00-50.40
VSN
Verseon
0.5$74.00-2.0%£127.41 millionN/A-5.17Gap Up
SBI
Sourcebio International
1.7$171.74-1.0%£126.11 millionN/A0.00
ANIC
Agronomics
0.5$24.85-3.4%£124.72 million£1.05 million-124.25High Trading Volume
News Coverage
Advanced Oncotherapy logo
AVO
Advanced Oncotherapy
0.4$33.00-3.0%£115.30 millionN/A-3.37High Trading Volume
ETX
e-therapeutics
0.4$27.30-5.5%£114.87 million£305,000.00-27.30News Coverage
Gap Down
Shield Therapeutics logo
STX
Shield Therapeutics
0.9$54.00-1.9%£112.24 million£10.39 million-24.55Upcoming Earnings
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$25.97-0.3%£107.66 millionN/A-0.79High Trading Volume
DXRX
Diaceutics
0.5$125.00-0.4%£105.09 million£12.70 million416.67News Coverage
Venture Life Group logo
VLG
Venture Life Group
0.7$83.50-0.6%£105.07 million£30.08 million33.40
SIS
Science in Sport
1.6$71.50-0.7%£96.60 million£50.35 million-55.00
IHC
Inspiration Healthcare Group
0.8$141.00-1.8%£96.05 million£36.98 million27.65
YGEN
Yourgene Health
0.4$13.00-1.9%£94.01 million£17.03 million-21.67
Diurnal Group logo
DNL
Diurnal Group
0.6$67.20-1.9%£92.96 million£6.38 million-16.39Insider Selling
SBTX
SkinBioTherapeutics
0.4$59.00-8.5%£92.50 millionN/A-59.00High Trading Volume
Georgia Healthcare Group PLC (GHG.L) logo
GHG
Georgia Healthcare Group PLC (GHG.L)
0.8$70.80-4.5%£91.67 millionN/A0.00
C4XD
C4X Discovery
0.6$40.00-5.0%£90.54 million£7.06 million-7.55
Destiny Pharma logo
DEST
Destiny Pharma
0.8$141.50-1.1%£84.71 million£12,450.00-11.79Gap Down
VRCI
Verici Dx
0.0$59.50-4.2%£84.34 millionN/A0.00Gap Up
SAR
Sareum
0.5$2.38-3.4%£77.61 million£47,204.00-7.15News Coverage
Immunodiagnostic Systems logo
IDH
Immunodiagnostic Systems
0.5$255.00-5.9%£73.40 million£34.25 million196.15Gap Down
ReNeuron Group logo
RENE
ReNeuron Group
0.6$127.50-3.5%£72.49 million£112,000.00-2.78News Coverage
OBD
Oxford BioDynamics
0.5$73.50-2.4%£68.03 million£456,000.00-15.64Gap Down
TLY
Totally
1.3$35.50-2.8%£64.68 million£110.83 million-177.50
ABDX
Abingdon Health
0.3$62.70-2.7%£58.38 millionN/A0.00Gap Up
IUG
Diurnal Group
0.0$18.20-2.5%£49.41 million£5.17 million-14.00High Trading Volume
Tissue Regenix Group logo
TRX
Tissue Regenix Group
0.9$0.69-1.4%£48.53 million£12.83 million-3.45
HVO
Hvivo
0.5$52.12-68.3%£43.61 million£12.09 million-2.61Gap Up
IXICO logo
IXI
IXICO
0.9$89.50-3.9%£42.93 million£9.53 million44.75
4BB
4basebio UK Societas
0.3$370.00-1.4%£42.49 millionN/A0.00High Trading Volume
genedrive logo
GDR
genedrive
0.6$67.00-3.7%£42.42 million£787,000.00-1.95
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.